Search

Your search keyword '"Cetnar, Jeremy Paul"' showing total 15 results
Start Over Author "Cetnar, Jeremy Paul"
15 results on '"Cetnar, Jeremy Paul"'

1. Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

Author

Galsky, Matthew D., Daneshmand, Siamak, Izadmehr, Sudeh, Gonzalez-Kozlova, Edgar, Chan, Kevin G., Lewis, Sara, Achkar, Bassam El, Dorff, Tanya B., Cetnar, Jeremy Paul, Neil, Brock O., D’Souza, Anishka, Mamtani, Ronac, Kyriakopoulos, Christos, Jun, Tomi, Gogerly-Moragoda, Mahalya, Brody, Rachel, Xie, Hui, Nie, Kai, Kelly, Geoffrey, Horowitz, Amir, Kinoshita, Yayoi, Ellis, Ethan, Nose, Yohei, Ioannou, Giorgio, Cabal, Rafael, Del Valle, Diane M., Haines, G. Kenneth, Wang, Li, Mouw, Kent W., Samstein, Robert M., Mehrazin, Reza, Bhardwaj, Nina, Yu, Menggang, Zhao, Qianqian, Kim-Schulze, Seunghee, Sebra, Robert, Zhu, Jun, Gnjatic, Sacha, Sfakianos, John, and Pal, Sumanta K.

Published
2023
Full Text
View/download PDF

2. Author Correction: Gemcitabine and cisplatin plus nivolumab as organ-sparing treatment for muscle-invasive bladder cancer: a phase 2 trial

Author

Galsky, Matthew D., Daneshmand, Siamak, Izadmehr, Sudeh, Gonzalez-Kozlova, Edgar, Chan, Kevin G., Lewis, Sara, Achkar, Bassam El, Dorff, Tanya B., Cetnar, Jeremy Paul, Neil, Brock O., D’Souza, Anishka, Mamtani, Ronac, Kyriakopoulos, Christos, Jun, Tomi, Gogerly-Moragoda, Mahalya, Brody, Rachel, Xie, Hui, Nie, Kai, Kelly, Geoffrey, Horowitz, Amir, Kinoshita, Yayoi, Ellis, Ethan, Nose, Yohei, Ioannou, Giorgio, Cabal, Rafael, Del Valle, Diane M., Haines, G. Kenneth, Wang, Li, Mouw, Kent W., Samstein, Robert M., Mehrazin, Reza, Bhardwaj, Nina, Yu, Menggang, Zhao, Qianqian, Kim-Schulze, Seunghee, Sebra, Robert, Zhu, Jun, Gnjatic, Sacha, Sfakianos, John, and Pal, Sumanta K.

Published
2024
Full Text
View/download PDF

3. A Timeline of Immune Checkpoint Inhibitor Approvals in Small Cell Lung Cancer

Author

Gill, Jennifer, Cetnar, Jeremy Paul, and Prasad, Vinay

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Lung Cancer, Rare Diseases, Cancer, Lung, Prevention, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, Good Health and Well Being, Clinical Trials as Topic, Drug Approval, Humans, Immune Checkpoint Inhibitors, Lung Neoplasms, Progression-Free Survival, Research Design, Small Cell Lung Carcinoma, Time Factors, United States, United States Food and Drug Administration, FDA, immunotherapy, small cell lung cancer, surrogate endpoints, Oncology and carcinogenesis
Abstract

In this commentary, we review the timeline of clinical trials and regulatory actions of approved immune checkpoint inhibitors for small cell lung cancer, discuss challenges faced by regulatory agencies, and highlight paradoxical lessons that emerge. Accelerated approvals may fail to expedite drugs to market in this setting and further research on overall survival benefit is needed to prove drug efficacy.

Published
2020

5. Co-primary endpoint analysis of HCRN GU 16-257: Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle-invasive bladder cancer (MIBC).

Author

Galsky, Matt D., primary, Daneshmand, Siamak, additional, Lewis, Sara C, additional, Chan, Kevin G., additional, Dorff, Tanya B., additional, Cetnar, Jeremy Paul, additional, Mamtani, Ronac, additional, Kyriakopoulos, Christos, additional, Gogerly-Moragoda, Mahalya, additional, Izadmehr, Sudeh, additional, Yu, Menggang, additional, Zhao, Qianqian, additional, Jun, Tomi, additional, Mehrazin, Reza, additional, Sfakianos, John P., additional, and Pal, Sumanta Monty, additional

Published
2023
Full Text
View/download PDF

6. Pilot trial of physical and cognitive changes related to fall risk in enzalutamide patients with castration-resistant prostate cancer (CRPC).

Author

Rodriguez, Victor, primary, Cameron, Michelle, additional, Winters-Stone, Kerri M., additional, Beer, Tomasz M., additional, Alumkal, Joshi J., additional, Cetnar, Jeremy Paul, additional, Thawani, Rajat, additional, Amery, Taylor, additional, Vuky, Jacqueline, additional, Bailey, Shawna, additional, and Graff, Julie N, additional

Published
2022
Full Text
View/download PDF

7. PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).

Author

Grivas, Petros, primary, Yin, Jun, additional, Koshkin, Vadim S, additional, Cole, Suzanne, additional, Jain, Rohit K., additional, Dreicer, Robert, additional, Cetnar, Jeremy Paul, additional, Sundi, Debasish, additional, Gartrell, Benjamin Adam, additional, Galsky, Matt D., additional, Sievers, Colin M, additional, Hahn, Noah M., additional, and Carducci, Michael Anthony, additional

Published
2021
Full Text
View/download PDF

8. Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.

Author

Galsky, Matt D., primary, Daneshmand, Siamak, additional, Chan, Kevin G., additional, Dorff, Tanya B., additional, Cetnar, Jeremy Paul, additional, O Neil, Brock, additional, D'souza, Anishka, additional, Mamtani, Ronac, additional, Kyriakopoulos, Christos, additional, Garcia, Philip, additional, Izadmehr, Sudeh, additional, Yu, Menggang, additional, Zhao, Qianqian, additional, Mehrazin, Reza, additional, Lewis, Sara C, additional, Sfakianos, John, additional, and Pal, Sumanta K., additional

Published
2021
Full Text
View/download PDF

9. PrE0807 phase Ib feasibility trial of neoadjuvant nivolumab (N)/lirilumab (L) in cisplatin-ineligible muscle-invasive bladder cancer (BC).

Author

Grivas, Petros, primary, Puligandla, Maneka, additional, Cole, Suzanne, additional, Courtney, Kevin Dale, additional, Dreicer, Robert, additional, Gartrell, Benjamin Adam, additional, Cetnar, Jeremy Paul, additional, Dall'era, Marc, additional, Galsky, Matt D., additional, Jain, Rohit K., additional, Maughan, Benjamin Louis, additional, Agarwal, Neeraj, additional, Koshkin, Vadim S, additional, Hahn, Noah M., additional, and Carducci, Michael Anthony, additional

Published
2019
Full Text
View/download PDF

11. Migration to next-generation sequencing and the identification of RET and ROS1 rearrangements plus PTEN and MET protein expression in tumor specimens from patients with lung adenocarcinomas: Lung Cancer Mutation Consortium (LCMC 2.0).

Author

Kris, Mark G., primary, Johnson, Bruce E., additional, Kwiatkowski, David J., additional, Wistuba, Ignacio Ivan, additional, Berry, Lynne D, additional, Haura, Eric B., additional, Socinski, Mark A., additional, Ramalingam, Suresh S., additional, Glisson, Bonnie S., additional, Waqar, Saiama Naheed, additional, Otterson, Gregory Alan, additional, Schiller, Joan H., additional, Garon, Edward B., additional, Cetnar, Jeremy Paul, additional, Politi, Katerina A, additional, Brahmer, Julie R., additional, Sequist, Lecia V., additional, Lovly, Christine Marie, additional, Kugler, Kelly, additional, and Bunn, Paul A., additional

Published
2015
Full Text
View/download PDF

15. Pilot study of veliparib (ABT-888) with temozolomide (TMZ) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

Author

Hussain, Maha, primary, Carducci, Michael Anthony, additional, Slovin, Susan F., additional, Cetnar, Jeremy Paul, additional, Qian, Jiang, additional, McKeegan, Evelyn Mary, additional, Litvinovich, Elizabeth, additional, Chyla, Brenda, additional, Hetman, Robert, additional, Desai, Bhardwaj, additional, Giranda, Vincent L., additional, and Alumkal, Joshi J., additional

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results